Rigontec
Company

Last deal

$25.99M
Local Amount - EUR 29.25M

Amount

Series A

Stage

06.09.2016

Date

1

all rounds

$25.99M

Total amount

date founded

Financing round

General

About Company
Ritontec is a leading company in the development of RNA therapeutics that target RIG-I.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2014

Operating Status

Closed (01.09.2017)

Number of employees

Company Type

For Profit

Last funding type

Series A

IPO status

Private

Description

Rigontec is the leader in RIG-I targeting RNA therapeutics developing novel immuno-oncology treatment options.
Similar Companies
1000
Iksuda Therapeutics

Iksuda Therapeutics

Iksuda Therapeutics develops next-generation biotherapeutics, including antibody drug conjugates (ADCs) for difficult-to-treat cancers.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Therapeutics, Health Care

Location

Newcastle upon Tyne, UK

total rounds

4

total raised

$51.98M
Capacity Bio

Capacity Bio

Capacity Bio develops advanced mitophagy therapeutics and a platform to restore mitochondrial quality control in disease.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Palo Alto, CA, USA

total rounds

2

total raised

$35M
ImCheck Therapeutics

ImCheck Therapeutics

ImCheck Therapeutics designs immunotherapy antibodies targeting butyrophilins and γ9δ2 T cells.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Marseille, France

total rounds

6

total raised

$185.47M
Evolve Biologics

Evolve Biologics

Evolve Biologics Inc. develops and commercializes plasma-derived therapeutics using its proprietary PlasmaCap EBA purification technology.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Pharmaceuticals

Location

Mississauga, ON, Canada

total rounds

1
M&A Details
1

Acquired by

Merck Sharp & Dohme Sweden AB

announced date

06.09.2017

price

$465M

Financials

Funding Rounds
1
1

Number of Funding Rounds

$25.99M

Money Raised

Their latest funding was raised on 06.09.2016. Their latest investor Forbion. Their latest round Series A

Date 
Funding Round 
Investors 
Money Raised 
Lead 
06.09.2016
7
$25.99M
Local Amount - EUR 29.25M
Forbion

Forbion

Netherlands-based venture capital firm investing in life sciences and MedTech companies.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Venture Capital, Biotechnology, Financial Services

Location

Naarden, Netherlands

count Of Investments

163

count Of Exists

68
Boehringer Ingelheim Venture Fund

Boehringer Ingelheim Venture Fund

Boehringer Ingelheim Venture Fund invests in therapeutic biotechnology companies.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Venture Capital, Biotechnology, Financial Services

Location

Ingelheim am Rhein, Germany

count Of Investments

69

count Of Exists

7
NRW.BANK

NRW.BANK

NRW.BANK is a financial group that supports investment and development in the NRW state of Germany.

Sector

Banks

Subsector

Banks

Keywords

Financial Services, Venture Capital, Finance

Location

Düsseldorf, Germany

count Of Investments

83

count Of Exists

11
Wellington Partners

Wellington Partners

Wellington Partners is a venture capital firm that invests in technology and life sciences companies.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Financial Services, Venture Capital, Biotechnology

Location

Munich, Germany

count Of Investments

205

count Of Exists

54
MP Healthcare Venture Management

MP Healthcare Venture Management

MP Healthcare Venture Management is a venture capital firm that invests in innovative research-driven companies.

Sector

Closed End Investments

Subsector

Closed End Investments

Location

Boston, MA, USA

count Of Investments

33

count Of Exists

7
High-Tech Grunderfonds

High-Tech Grunderfonds

High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven start-ups.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

Bonn, Germany

count Of Investments

828

count Of Exists

107
Co-Investors
Investors
7
6

Number of lead investors

7

Number of investors

Investor 
Lead 
Round 
Partners 
Yes
Series A
Yes
Series A
Forbion

Forbion

Netherlands-based venture capital firm investing in life sciences and MedTech companies.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Venture Capital, Biotechnology, Financial Services

Location

Naarden, Netherlands

count Of Investments

163

count Of Exists

68
Boehringer Ingelheim Venture Fund

Boehringer Ingelheim Venture Fund

Boehringer Ingelheim Venture Fund invests in therapeutic biotechnology companies.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Venture Capital, Biotechnology, Financial Services

Location

Ingelheim am Rhein, Germany

count Of Investments

69

count Of Exists

7
NRW.BANK

NRW.BANK

NRW.BANK is a financial group that supports investment and development in the NRW state of Germany.

Sector

Banks

Subsector

Banks

Keywords

Financial Services, Venture Capital, Finance

Location

Düsseldorf, Germany

count Of Investments

83

count Of Exists

11

People

Founders
6

Veit Hornung

organization founded

1

Veit Hornung

Marcel Renn
Marcel Renn

Marcel Renn

Marcel Renn is the Workgroup Leader of Department of Clinical Chemistry and Clinical Pharmacology at University Hospital Bonn.

current job

University Hospital Bonn
University Hospital Bonn

organization founded

1

Marcel Renn

Annegret Baey-Diepolder
Annegret Baey-Diepolder

Annegret Baey-Diepolder

Annegret Baey-Diepolder is Member Board Of Directors of Abalos Therapeutics GmbH.

current job

Abalos Therapeutics
Abalos Therapeutics

organization founded

1

Annegret Baey-Diepolder

Christine Schuberth Wagner
Christine Schuberth Wagner

Christine Schuberth Wagner

Christine Schuberth-Wagner is a co-founder of Rigontec, and obtained her Ph.D. on the molecular interaction of RNA with RIG-I, which included the development of Rigontec’s lead compound. Prior to co-founding Rigontec, she worked as a project manager and GO-Bio project leader at the Institute for Clinical Chemistry and Clinical Pharmacology at the University of Bonn. Christine Schuberth-Wagner studied human biology at the University of Marburg and took part in the MBA BioMedTech program at the University of Potsdam. She holds a Ph.D. in molecular biomedicine from the University of Bonn.

current job

Catalym
Catalym

organization founded

1

Christine Schuberth Wagner

Employee Profiles
7
Anne Burger

Anne Burger

CFO

Manuela Niewel

SVP Clinical

Anna Schwickart-Halbe

Anna Schwickart-Halbe

Founder

Activity

Recent News
0